Literature DB >> 28060367

Applications of molecular testing in surgical pathology of the head and neck.

Jennifer L Hunt1.   

Abstract

Molecular testing in routine surgical pathology is becoming an important component of the workup of many different types of tumors. In fact, in some organ systems, guidelines now suggest that the standard of care is to obtain specific molecular panels for tumor classification and/or therapeutic planning. In the head and neck, clinically applicable molecular tests are not as abundant as in other organ systems. Most current head and neck biomarkers are utilized for diagnosis rather than as companion diagnostic tests to predict therapeutic response. As the number of potential molecular biomarker assays increases and cost pressures escalate, the pathologist must be able to navigate the molecular testing pathways. This review explores scenarios in which molecular testing might be beneficial and cost-effective in head and neck pathology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28060367     DOI: 10.1038/modpathol.2016.192

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  90 in total

Review 1.  What Accountable Care Organizations Can Learn from Kaiser Permanente California's Acute Care Strategy.

Authors:  Jeffrey Selevan; Dana Kindermann; Jesse M Pines; Wm Wesley Fields
Journal:  Popul Health Manag       Date:  2015-04-09       Impact factor: 2.459

2.  The triple aim: care, health, and cost.

Authors:  Donald M Berwick; Thomas W Nolan; John Whittington
Journal:  Health Aff (Millwood)       Date:  2008 May-Jun       Impact factor: 6.301

3.  Improving Molecular Genetic Test Utilization through Order Restriction, Test Review, and Guidance.

Authors:  Jacquelyn D Riley; Gary W Procop; Kandice Kottke-Marchant; Robert Wyllie; Felicitas L Lacbawan
Journal:  J Mol Diagn       Date:  2015-02-27       Impact factor: 5.568

Review 4.  Adenoid cystic carcinoma of the head and neck--An update.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Patrick J Bradley; Vincent Vander Poorten; Asterios Triantafyllou; Jennifer L Hunt; Primož Strojan; Alessandra Rinaldo; Missak Haigentz; Robert P Takes; Vanni Mondin; Afshin Teymoortash; Lester D R Thompson; Alfio Ferlito
Journal:  Oral Oncol       Date:  2015-05-02       Impact factor: 5.337

5.  Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.

Authors:  Ching-Hung Lin; Roh-Fan Yen; Yung-Ming Jeng; Chin-Yuan Tzen; Chiun Hsu; Ruey-Long Hong
Journal:  Head Neck       Date:  2005-12       Impact factor: 3.147

Review 6.  MYB-fusions and other potential actionable targets in adenoid cystic carcinoma.

Authors:  Renata Ferrarotto; John V Heymach; Bonnie S Glisson
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

7.  Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Authors:  S J Wong; T Karrison; D N Hayes; M S Kies; K J Cullen; T Tanvetyanon; A Argiris; N Takebe; D Lim; N F Saba; F P Worden; J Gilbert; H J Lenz; A R A Razak; J D Roberts; E E Vokes; E E W Cohen
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

8.  Evaluation of NKX2-2 expression in round cell sarcomas and other tumors with EWSR1 rearrangement: imperfect specificity for Ewing sarcoma.

Authors:  Yin P Hung; Christopher D M Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2016-02-05       Impact factor: 7.842

9.  Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing.

Authors:  Olivier Harismendy; Richard B Schwab; Lei Bao; Jeff Olson; Sophie Rozenzhak; Steve K Kotsopoulos; Stephanie Pond; Brian Crain; Mark S Chee; Karen Messer; Darren R Link; Kelly A Frazer
Journal:  Genome Biol       Date:  2011-12-20       Impact factor: 13.583

Review 10.  Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance.

Authors:  Felix Schmidt; Thomas Efferth
Journal:  Pharmaceuticals (Basel)       Date:  2016-06-16
View more
  1 in total

Review 1.  Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma.

Authors:  Florencia Veigas; Yamil D Mahmoud; Joaquin Merlo; Adriana Rinflerch; Gabriel Adrian Rabinovich; María Romina Girotti
Journal:  Cancers (Basel)       Date:  2021-03-01       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.